These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 21263312)

  • 1. Targeted therapies in malignant pleural mesothelioma: a review of clinical studies.
    Greillier L; Marco S; Barlesi F
    Anticancer Drugs; 2011 Mar; 22(3):199-205. PubMed ID: 21263312
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Review on clinical trials of targeted treatments in malignant mesothelioma.
    Jakobsen JN; Sørensen JB
    Cancer Chemother Pharmacol; 2011 Jul; 68(1):1-15. PubMed ID: 21553148
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined chemotherapy with cytotoxic and targeted compounds for the management of human malignant pleural mesothelioma.
    Favoni RE; Florio T
    Trends Pharmacol Sci; 2011 Aug; 32(8):463-79. PubMed ID: 21620489
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advances in the systemic therapy of malignant pleural mesothelioma.
    Fennell DA; Gaudino G; O'Byrne KJ; Mutti L; van Meerbeeck J
    Nat Clin Pract Oncol; 2008 Mar; 5(3):136-47. PubMed ID: 18227828
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Malignant pleural mesothelioma: current treatments and emerging drugs.
    Belli C; Fennell D; Giovannini M; Gaudino G; Mutti L
    Expert Opin Emerg Drugs; 2009 Sep; 14(3):423-37. PubMed ID: 19552609
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-angiogenic therapies for malignant pleural mesothelioma.
    Ceresoli GL; Zucali PA
    Expert Opin Investig Drugs; 2012 Jun; 21(6):833-44. PubMed ID: 22519641
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Translational therapies for malignant pleural mesothelioma.
    Belli C; Anand S; Tassi G; Fennell D; Mutti L
    Expert Rev Respir Med; 2010 Apr; 4(2):249-60. PubMed ID: 20406091
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Guidelines of the French Speaking Society for Chest Medicine for management of malignant pleural mesothelioma.
    Scherpereel A;
    Respir Med; 2007 Jun; 101(6):1265-76. PubMed ID: 17137779
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in the biology of malignant pleural mesothelioma.
    Zucali PA; Ceresoli GL; De Vincenzo F; Simonelli M; Lorenzi E; Gianoncelli L; Santoro A
    Cancer Treat Rev; 2011 Nov; 37(7):543-58. PubMed ID: 21288646
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted epidermal growth factor receptor therapy in malignant pleural mesothelioma: where do we stand?
    Agarwal V; Lind MJ; Cawkwell L
    Cancer Treat Rev; 2011 Nov; 37(7):533-42. PubMed ID: 21183281
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Malignant pleural mesothelioma: current concepts in treatment.
    Tsiouris A; Walesby RK
    Nat Clin Pract Oncol; 2007 Jun; 4(6):344-52. PubMed ID: 17534390
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular targets in malignant pleural mesothelioma treatment.
    Pasello G; Favaretto A
    Curr Drug Targets; 2009 Dec; 10(12):1235-44. PubMed ID: 19909234
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Malignant pleural mesothelioma.
    Chen SE; Pace MB
    Am J Health Syst Pharm; 2012 Mar; 69(5):377-85. PubMed ID: 22345416
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Malignant pleural mesothelioma: diagnosis and treatment].
    Delourme J; Dhalluin X; Cortot AB; Lafitte JJ; Scherpereel A
    Rev Pneumol Clin; 2013 Feb; 69(1):26-35. PubMed ID: 23333048
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systemic approach to malignant pleural mesothelioma: what news of chemotherapy, targeted agents and immunotherapy?
    Signorelli D; Macerelli M; Proto C; Vitali M; Cona MS; Agustoni F; Zilembo N; Platania M; Trama A; Gallucci R; Ganzinelli M; Pelosi G; Pastorino U; de Braud F; Garassino MC; Lo Russo G
    Tumori; 2016; 102(1):18-30. PubMed ID: 26481865
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of Alimta in the treatment of malignant pleural mesothelioma: an overview of preclinical and clinical trials.
    Hanauske AR
    Lung Cancer; 2004 Aug; 45 Suppl 1():S121-4. PubMed ID: 15261444
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Malignant mesothelioma 2008.
    Zervos MD; Bizekis C; Pass HI
    Curr Opin Pulm Med; 2008 Jul; 14(4):303-9. PubMed ID: 18520263
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SU6668, a multiple tyrosine kinase inhibitor, inhibits progression of human malignant pleural mesothelioma in an orthotopic model.
    Van TT; Hanibuchi M; Goto H; Kuramoto T; Yukishige S; Kakiuchi S; Sato S; Sakaguchi S; Dat le T; Nishioka Y; Akiyama S; Sone S
    Respirology; 2012 Aug; 17(6):984-90. PubMed ID: 22574723
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Malignant pleural mesothelioma: a new standard of care.
    Stahel RA
    Lung Cancer; 2006 Dec; 54 Suppl 2():S9-S14. PubMed ID: 17059852
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biology and management of malignant pleural mesothelioma.
    Zucali PA; Giaccone G
    Eur J Cancer; 2006 Nov; 42(16):2706-14. PubMed ID: 16989994
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.